Collplant Holdings Ltd's (OTC:CQPTY) Q317 marked continued commercial progress and increasing interest in its plant-based recombinant human collagen (rhCollagen) based technology. It announced multiple sales of its bioInk product for 3D tissue printing to a major biotechnology company and a major medical device company, which is very encouraging and potentially validating. Additionally, it expanded its commercial footprint for VergenixFG to Greece and Cyprus with a new distribution deal.
New contracts for bioInk
CollPlant has announced that it has received multiple orders for its bioInk product for the 3D printing of organs and tissues. It received its first order in September from a major biotechnology company, which subsequently reordered more product valued in the hundreds of thousands of dollars. The company intends to use the product to print organs for transplant. Additionally, CollPlant has received an order from a major medical device company in the order of multiple tens of thousands of dollars to develop a 3D printed orthopaedic implant.
To read the entire report Please click on the pdf File Below: